InSilico Medicine Signs CNS Drug Deal With Hygtia Therapeutics; Shares Up 4%

MT Newswires Live01-20 10:15

InSilico Medicine (HKG:3696) entered into a global licensing and co-development agreement with Hygtia Therapeutics to advance its ISM8969 program, valuing the deal at up to HK$514.8 million, according to a Tuesday Hong Kong bourse filing.

Hygtia Therapeutics is an incubate of Shenzhen Pengfu Biopharmaceutical Industry Private Equity Investment Fund Partnership Enterprise of Fosun Health Capital and Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196).

Under the agreement, Insilico and Hygtia will co-develop ISM8969, an oral, brain-penetrant NLRP3 inhibitor for central nervous system (CNS) disorders, with each party holding 50% of the global rights.

Insilico is eligible to receive up to $66 million in upfront and milestone payments, including a $10 million upfront payment due within 30 days, the filing said.

InSilico shares rose nearly 4% in morning trade Tuesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment